EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Inhibitory potential of polyphenolic stilbene derivatives with Glycogen Synthase Kinase-3β (GSK-3β) for Alzheimer's disease: Computational and SAR insights

Santosh Prasad Chaudhary Kurmi, Dipanjan Karati

Brain Disorders · 2025-03 · 17 · 100182

DOI: 10.1016/j.dscb.2025.100182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Disorders, 2025-03. Verfasst von Santosh Prasad Chaudhary Kurmi und 1 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disorder. Beta-amyloid plaques and tau protein tangles emerge in the brain as pathological hallmarks of AD. One important enzyme involved in tau phosphorylation, Glycogen Synthase Kinase-3β (GSK-3β), has become a viable therapeutic target for AD. A new approach to AD intervention is provided by polyphenolic stilbene derivatives, which are well-known for their wide range of biological activities and show strong inhibitory capability against GSK-3β. This work uses computational methods, such as molecular docking, binding energy analysis, and structure-activity relationship (SAR) insights, to investigate the inhibitory action of polyphenolic stilbene derivatives. Molecular docking and MD-simulation of the best docked Piceid (C12) compounds were used to analyze the backbone stability and conformational binding affinity with the target protein GSK-3β. The SAR of Piceid and GSK-3β protein was specifically examined as the primary candidate target. Furthermore, binding free energy (MMGBSA), drug-likeness and toxicity, medicinal chemistry parameters were investigated in support to be lead compound for drug discovery. The molecular docking binding affinity of Piceid (C12) compound was found -8.8 Kcal/mol which is higher than GSK-3β inhibitor standard compound Laduviglusib (C18) has binding energy -8.7 Kcal/mol. These results imply that piceid has potential as an AD treatment because to its favorable interaction profile and high binding affinity.

Zitieren

APA

Kurmi, S. P. C., & Karati, D. (2025). Inhibitory potential of polyphenolic stilbene derivatives with Glycogen Synthase Kinase-3β (GSK-3β) for Alzheimer's disease: Computational and SAR insights. Brain Disorders, 17, 100182. https://doi.org/10.1016/j.dscb.2025.100182

Vancouver

Kurmi SPC, Karati D. Inhibitory potential of polyphenolic stilbene derivatives with Glycogen Synthase Kinase-3β (GSK-3β) for Alzheimer's disease: Computational and SAR insights. Brain Disorders. 2025;17:100182. doi:10.1016/j.dscb.2025.100182

BibTeX
@article{Kurmi2025,
  author = {Kurmi, Santosh Prasad Chaudhary and Karati, Dipanjan},
  title = {Inhibitory potential of polyphenolic stilbene derivatives with Glycogen Synthase Kinase-3β (GSK-3β) for Alzheimer's disease: Computational and SAR insights},
  journal = {Brain Disorders},
  year = {2025},
  volume = {17},
  pages = {100182},
  doi = {10.1016/j.dscb.2025.100182}
}
Kostenlos starten →